The ER-positive / PgR-negative breast cancer phenotype is not associated with mutations within the DNA binding domain

Suzanne A W Fuqua, D. Craig Allred, Richard M. Elledge, Shelly L. Krieg, Margaret G. Benedix, Zafar Nawaz, Bert W. O'Malley, Geoffrey L. Greene, William L. McGuire

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

We have used in vitro DNA binding assays as a measure of estrogen receptor (ER) function in human breast tumors. We found that the majority of ER+ (25 ER+/progesterone receptor [PgR]+, and 25 ER+/PgR-) tumors we examined were capable of binding consensus estrogen response element (ERE) oligonucleotides in this assay system. We found significant proteolytic activity in many of the tumors such that protease inhibitors were found to be essential during the preparation of tumor extracts. We next applied direct sequence analysis of the ER DNA binding domain of several of these tumors, and determined that the ER+/PgR- breast tumors did not contain mutations within the DNA binding domain which might explain their apparent discordant receptor phenotype. We did identify an alternatively spliced ER variant missing exon 3 of the DNA binding domain. This variant was unable to function as a transcriptional inducer of an estrogen-responsive reporter in a yeast assay system. Furthermore, the exon 3 ER deletion variant was expressed at equivalent levels in all of the ER+ breast tumors, so that it does not appear to be involved in the evolution of the ER+/PgR- breast cancer phenotype.

Original languageEnglish
Pages (from-to)191-202
Number of pages12
JournalBreast Cancer Research and Treatment
Volume26
Issue number2
DOIs
StatePublished - Jan 1 1993
Externally publishedYes

Fingerprint

Progesterone Receptors
Estrogen Receptors
Breast Neoplasms
Phenotype
Mutation
DNA
Exons
Neoplasms
Estrogens
Response Elements
Protease Inhibitors
Oligonucleotides
Sequence Analysis
Yeasts

Keywords

  • breast cancer
  • DNA binding domain
  • estrogen receptor
  • gel-retardation analysis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

The ER-positive / PgR-negative breast cancer phenotype is not associated with mutations within the DNA binding domain. / Fuqua, Suzanne A W; Allred, D. Craig; Elledge, Richard M.; Krieg, Shelly L.; Benedix, Margaret G.; Nawaz, Zafar; O'Malley, Bert W.; Greene, Geoffrey L.; McGuire, William L.

In: Breast Cancer Research and Treatment, Vol. 26, No. 2, 01.01.1993, p. 191-202.

Research output: Contribution to journalArticle

Fuqua, SAW, Allred, DC, Elledge, RM, Krieg, SL, Benedix, MG, Nawaz, Z, O'Malley, BW, Greene, GL & McGuire, WL 1993, 'The ER-positive / PgR-negative breast cancer phenotype is not associated with mutations within the DNA binding domain', Breast Cancer Research and Treatment, vol. 26, no. 2, pp. 191-202. https://doi.org/10.1007/BF00689692
Fuqua, Suzanne A W ; Allred, D. Craig ; Elledge, Richard M. ; Krieg, Shelly L. ; Benedix, Margaret G. ; Nawaz, Zafar ; O'Malley, Bert W. ; Greene, Geoffrey L. ; McGuire, William L. / The ER-positive / PgR-negative breast cancer phenotype is not associated with mutations within the DNA binding domain. In: Breast Cancer Research and Treatment. 1993 ; Vol. 26, No. 2. pp. 191-202.
@article{e088d159ebfb4e4ebe7c486eac32170b,
title = "The ER-positive / PgR-negative breast cancer phenotype is not associated with mutations within the DNA binding domain",
abstract = "We have used in vitro DNA binding assays as a measure of estrogen receptor (ER) function in human breast tumors. We found that the majority of ER+ (25 ER+/progesterone receptor [PgR]+, and 25 ER+/PgR-) tumors we examined were capable of binding consensus estrogen response element (ERE) oligonucleotides in this assay system. We found significant proteolytic activity in many of the tumors such that protease inhibitors were found to be essential during the preparation of tumor extracts. We next applied direct sequence analysis of the ER DNA binding domain of several of these tumors, and determined that the ER+/PgR- breast tumors did not contain mutations within the DNA binding domain which might explain their apparent discordant receptor phenotype. We did identify an alternatively spliced ER variant missing exon 3 of the DNA binding domain. This variant was unable to function as a transcriptional inducer of an estrogen-responsive reporter in a yeast assay system. Furthermore, the exon 3 ER deletion variant was expressed at equivalent levels in all of the ER+ breast tumors, so that it does not appear to be involved in the evolution of the ER+/PgR- breast cancer phenotype.",
keywords = "breast cancer, DNA binding domain, estrogen receptor, gel-retardation analysis",
author = "Fuqua, {Suzanne A W} and Allred, {D. Craig} and Elledge, {Richard M.} and Krieg, {Shelly L.} and Benedix, {Margaret G.} and Zafar Nawaz and O'Malley, {Bert W.} and Greene, {Geoffrey L.} and McGuire, {William L.}",
year = "1993",
month = "1",
day = "1",
doi = "10.1007/BF00689692",
language = "English",
volume = "26",
pages = "191--202",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - The ER-positive / PgR-negative breast cancer phenotype is not associated with mutations within the DNA binding domain

AU - Fuqua, Suzanne A W

AU - Allred, D. Craig

AU - Elledge, Richard M.

AU - Krieg, Shelly L.

AU - Benedix, Margaret G.

AU - Nawaz, Zafar

AU - O'Malley, Bert W.

AU - Greene, Geoffrey L.

AU - McGuire, William L.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - We have used in vitro DNA binding assays as a measure of estrogen receptor (ER) function in human breast tumors. We found that the majority of ER+ (25 ER+/progesterone receptor [PgR]+, and 25 ER+/PgR-) tumors we examined were capable of binding consensus estrogen response element (ERE) oligonucleotides in this assay system. We found significant proteolytic activity in many of the tumors such that protease inhibitors were found to be essential during the preparation of tumor extracts. We next applied direct sequence analysis of the ER DNA binding domain of several of these tumors, and determined that the ER+/PgR- breast tumors did not contain mutations within the DNA binding domain which might explain their apparent discordant receptor phenotype. We did identify an alternatively spliced ER variant missing exon 3 of the DNA binding domain. This variant was unable to function as a transcriptional inducer of an estrogen-responsive reporter in a yeast assay system. Furthermore, the exon 3 ER deletion variant was expressed at equivalent levels in all of the ER+ breast tumors, so that it does not appear to be involved in the evolution of the ER+/PgR- breast cancer phenotype.

AB - We have used in vitro DNA binding assays as a measure of estrogen receptor (ER) function in human breast tumors. We found that the majority of ER+ (25 ER+/progesterone receptor [PgR]+, and 25 ER+/PgR-) tumors we examined were capable of binding consensus estrogen response element (ERE) oligonucleotides in this assay system. We found significant proteolytic activity in many of the tumors such that protease inhibitors were found to be essential during the preparation of tumor extracts. We next applied direct sequence analysis of the ER DNA binding domain of several of these tumors, and determined that the ER+/PgR- breast tumors did not contain mutations within the DNA binding domain which might explain their apparent discordant receptor phenotype. We did identify an alternatively spliced ER variant missing exon 3 of the DNA binding domain. This variant was unable to function as a transcriptional inducer of an estrogen-responsive reporter in a yeast assay system. Furthermore, the exon 3 ER deletion variant was expressed at equivalent levels in all of the ER+ breast tumors, so that it does not appear to be involved in the evolution of the ER+/PgR- breast cancer phenotype.

KW - breast cancer

KW - DNA binding domain

KW - estrogen receptor

KW - gel-retardation analysis

UR - http://www.scopus.com/inward/record.url?scp=0027328914&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027328914&partnerID=8YFLogxK

U2 - 10.1007/BF00689692

DO - 10.1007/BF00689692

M3 - Article

VL - 26

SP - 191

EP - 202

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -